Creative Life Science, a leading brand in microbiological testing, is set to be listed on Taiwan’s Emerging Stock Market on May 28. The recommended subscription price from brokers is NT$85 per share. Chairman and General Manager Tsai, Yueh-Ting noted that the company has demonstrated solid operational performance in recent years, with earnings per share (EPS) of NT$4.5 in 2024, underscoring strong profitability. Moving forward, the company will pursue growth through three strategic directions.
With a history of over 45 years, Creative Life Science began with clinical diagnostics and physical products, gradually building its own brand and entering broader market channels. As the industry evolved, the company expanded horizontally from clinical diagnostics into areas such as biotech data, regenerative medicine, and food safety, accumulating more than four decades of R&D experience and proven market results. It has established a strong presence at the upstream end of supply chains across biopharmaceuticals, third-party testing, medical diagnostics, and the food industry, and has developed over 600 proprietary products to date, including standardized offerings and customized applications.
In 2024, the company completed its first round of cash capital increase, bringing in strategic investors with international perspectives and solid capital backgrounds. The current shareholding structure includes approximately 71% held by the management team, 21% by strategic investors, 13% by employees, and the remaining 5% held by others. Notable strategic investors include Taishin Health Venture Capital (5.29%), IEI Integration Corp. (4.03%), Bora Pharmaceuticals (2.09%), LSK BioPharma (1.66%), and Taiwan Cooperative Venture Capital (1.32%).
Revenue in 2024 reached NT$860 million, marking a 25% increase from NT$680 million in 2023. Gross profit rose from NT$250 million to NT$340 million, while net income after tax grew to NT$95 million, up 27% from NT$74 million the previous year. EPS stood at NT$4.5, reflecting robust earnings momentum.
Looking ahead, Tsai outlined the company’s three core strategies. First, to continue increasing its market share in core business operations by leveraging its established position in the biopharmaceutical supply chain to help clients bring products to market faster and gain competitive advantages. Second, to develop new ventures in regenerative medicine by establishing a full supply chain for the sector. This includes completing a PIC/S GMP-compliant facility in Zhubei this year and collaborating with leading domestic clients. Third, to strengthen industry partnerships by working closely with strategic investors to integrate upstream and downstream resources through investments or acquisitions, thereby expanding the biotech and pharmaceutical ecosystem.
Beyond its core operations, the company is also focusing on a second growth curve targeting the cell and gene therapy (CGT)/advanced therapy medicinal products (ATMP) market, aiming to tap into opportunities in contract development and manufacturing (CDMO) and clinical research (CRO). In 2023, the company announced an investment of NT$350 million to build Taiwan’s first PIC/S GMP-compliant cell culture media and reagent facility in the Hsinchu Biomedical Science Park. This facility will also provide CDMO services for cell culture media and CGT-related contract research and testing services. It is expected to be completed this year and receive certification in 2026, positioning the company as a key service base in Taiwan for regenerative medicine CDMO/CRO that aligns with international regulatory standards.
Looking to 2025, the company anticipates maintaining double-digit revenue growth, driven by core business development and returns from strategic investments. In response to evolving customer needs and market trends, Creative Life Science will continue investing resources to sustain long-term competitive advantages and business growth potential. The goal remains to strengthen industry collaboration, integrate the biotech and pharmaceutical value chain with the help of strategic investors, and expand the overall ecosystem.
Resource: 啟新生技28日登興櫃 營運啟動三大成長策略
